TICKERNERD
Menu
CTXRCTXRHealthcare · Biotechnology

CTXR Stock Forecast: Citius Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.60
+0.07% on the day

The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +566.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.5M
Ticker Nerd rank
20 / 100
Median analyst target
$4.00
Analysts covering
1
Total return, dividends reinvested
1W
−20.6%
1M
+9.9%
YTD
−22.8%
1Y
−51.2%
From 52W high
−67.0%
From 52W low
+24.8%
$0.48
$1.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTXR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Citius Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Quality
68
Growth
38
Accruals
38
Revisions
32
Volatility
24
Value
21
Momentum
17
Issuance
10

Size (90): Smaller than most of the companies we track.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTXR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTXR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26CTXRHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +566.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.AssumesBuy$4.00
11 Mar 2026D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
13 Aug 2025D. Boral CapitalMaintainsBuy—
30 June 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
9 June 2025D. Boral CapitalMaintainsBuy—
23 May 2025Maxim GroupDowngradeHold—
15 May 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
7 Jan 2025D. Boral CapitalMaintainsBuy—
30 Dec 2024D. Boral CapitalUpgradeBuy—
22 Nov 2024D. Boral CapitalDowngradeHold—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024D. Boral CapitalMaintainsBuy—
19 Aug 2024EF HuttonMaintainsBuy—
8 Aug 2024EF HuttonMaintainsBuy—
5 Aug 2024EF HuttonMaintainsBuy—
15 July 2024EF HuttonInitiatesBuy—
31 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTXR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTXR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−212.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Citius Pharmaceuticals, Inc. (CTXR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
2.9×

Cheaper than 43% of US stocks

Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
−0.5×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−57.7%

Higher than 4% of US stocks

Earnings growth (YoY)
—
Gross margin
80.3%

Higher than 91% of US stocks

Operating margin
−1827.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−83.6%

Higher than 15% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CTXR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTXRCitius Pharmaceuticals, Inc.$16.5M
20
BIVIBioVie, Inc.$16.5M
22
PTNPalatin Technologies, Inc.$16.5M
43
PBMPsyence Biomedical Ltd.$16.5M
3
TPSTTempest Therapeutics, Inc.$16.6M
36
ADILAdial Pharmaceuticals, Inc.$16.3M
21
LPCNLipocine, Inc.$16.8M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Citius Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTXR news & analysis

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026neutral

Citius Pharmaceuticals reported fiscal third quarter 2026 financial results, noting $7.1 million in revenue for the first nine months from commercial sales of LYMPHIR, $17 million in cash as of June 30, 2026, and an expanded LYMPHIR commercial and medical affairs presence nationwide. The company also provided a business update on its majority-owned subsidiary, Citius Oncology.

Why it matters — The update highlights LYMPHIR's commercial traction and the company's cash position, giving CTXR watchers a current snapshot of the business.

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026positive

Citius Oncology, Inc., a majority-owned subsidiary of Citius Pharmaceuticals, reported fiscal third quarter 2026 financial results and provided a business update. The company reported $7.1 million in revenue for the first nine months of fiscal 2026 as the launch of LYMPHIR progresses, with strong institutional demand driving growth in total vials ordered and the number of institutions ordering LYMPHIR, which has been ordered by 44 institutions since launch.

Why it matters — As a majority-owned subsidiary of CTXR, Citius Oncology's LYMPHIR launch progress and reported revenue indicate how the commercial-stage product is performing for the parent company's watchers.

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

PRNewsWire · 12 Aug 2026neutral

Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D. as an independent director.

Why it matters — Since Citius Oncology is a majority-owned subsidiary of Citius Pharma, changes to its board leadership are relevant to CTXR shareholders following the subsidiary's governance.

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

PRNewsWire · 5 Aug 2026positive

Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, reported commercial momentum for its cancer treatment LYMPHIR, noting new institutional accounts ordering the drug increased 78% quarter over quarter, near-universal payer coverage expanding market access, and an initial cutaneous T-cell lymphoma market currently exceeding $400 million.

Why it matters — Since Citius Pharma holds a majority stake in Citius Oncology, strength in LYMPHIR's commercial rollout (institutional ordering and payer coverage) bears directly on CTXR shareholders.

FAQ

Frequently asked questions about CTXR stock

What is the CTXR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTXR stock a buy right now?

Of the 1 analysts covering Citius Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Pharmaceuticals, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTXR?

As at 22 Aug 2026, Citius Pharmaceuticals, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will CTXR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +566.4% from the last close, and Ticker Nerd's factor model ranks Citius Pharmaceuticals, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTXR stock forecast for 2030?

No analyst covering Citius Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CTXR stock performed over the past year?

Citius Pharmaceuticals, Inc. returned -51.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Citius Pharmaceuticals, Inc. do?

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products.

What is the latest news on CTXR?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update". Citius Pharmaceuticals reported fiscal third quarter 2026 financial results, noting $7.1 million in revenue for the first nine months from commercial sales of LYMPHIR, $17 million in cash as of June 30, 2026, and an expanded LYMPHIR commercial and medical affairs presence nationwide. The company also provided a business update on its majority-owned subsidiary, Citius Oncology.

Company

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Its diverse pipeline includes candidates targeting serious medical conditions, reflecting a commitment to advancing treatments that address critical unmet needs in healthcare. With a strategic emphasis on critical care and oncology-related therapeutics, Citius plays a significant role in the pharmaceutical industry by aiming to improve patient outcomes through novel drug development. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals leverages its clinical expertise to progress products through late-stage development toward commercialization.

CEO Mr. Leonard L. Mazur · 23 employees · United States · https://citiuspharma.com